Monoclonal Antibody and Peptide Targeted Radiotherapy of CancerMonoclonal Antibody and Peptide Targeted Radiotherapy of Cancer

Unique aspects of the book include: A translational focus on development, preclinical, and clinical evaluation of novel targeted radiopharmaceuticals for treating cancer A discussion on health economics issues that have an impact on the ...

Author: Raymond M. Reilly

Publisher: John Wiley & Sons

ISBN: 1118035151


Page: 648

View: 167

Oncology Book of 2011, British Medical Association's Medical Book Awards Awarded first prize in the Oncology category at the 2011 BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments. Expert discussion covers a range of diverse topics associated with this field, including the optimization of design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from key clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. With chapters authored by internationally renowned experts, this book delivers a wealth of information to push future discovery.

Targeted Radionuclide TherapyTargeted Radionuclide Therapy

Offering an overview of radioimmunotherapy, this book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy.

Author: Tod W. Speer

Publisher: Lippincott Williams & Wilkins

ISBN: 9780781796934


Page: 564

View: 700

Offering an overview of radioimmunotherapy, this book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy.

Nuclear Medicine TherapyNuclear Medicine Therapy

Release Criteria and Other Radiation Safety Considerations for Radionuclide Therapy. Upton AC. Radiation hormesis: data and ... Monoclonal antibody and peptide-targeted radiotherapy of malignancies. Hoboken, NJ: Wiley; 2010. p. 139–67.

Author: Cumali Aktolun

Publisher: Springer Science & Business Media

ISBN: 9781461440215


Page: 443

View: 153

Nuclear Medicine Therapy presents the state of the art in targeted radionuclide therapy, both in clinical practice and contemporary clinical investigation and trials. With contributions from an internationally-distinguished group of physicians and scientists, the book is devoted entirely to the use of nuclear medicine techniques and technology for therapy of malignant and benign diseases. Individual chapters cover the scientific principles and clinical applications of radionuclide therapy and the state of clinical trials of agents currently under investigation in the therapy of tumors involving virtually every organ system. Due to overlapping interest in techniques, indications, and clinical use, the development of radionuclide therapy attracts considerable input from other medical specialists whose collaboration is essential, including radiation and medical oncologists, hematologists, diagnostic radiologists, hepatologists, endocrinologists, and rheumatologists. And because radionuclide therapy is a rapidly evolving field of nuclear medicine, it is the aim of this volume to appeal to all specialists involved in targeted radionuclide therapy and to contribute to the standardization of the practice globally.

Biological Drug ProductsBiological Drug Products

Selected regulatory elements in the development of protein and peptide targeted radiotherapeutic agents. In: Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. Hoboken, NJ: John Wiley & Sons, Inc.; 2010. p. 571—611. 291.

Author: Wei Wang

Publisher: John Wiley & Sons

ISBN: 9781118695227


Page: 744

View: 842

Tested and proven solutions to the challenges of biologicaldrug product development Biological drug products play a central role in combating humandiseases; however, developing new successful biological drugspresents many challenges, including labor intensive productionprocesses, tighter regulatory controls, and increased marketcompetition. This book reviews the current state of the science,offering readers a single resource that sets forth the fundamentalsas well as tested and proven development strategies for biologicaldrugs. Moreover, the book prepares readers for the challenges thattypically arise during drug development, offering straightforwardsolutions to improve their ability to pass through all theregulatory hurdles and deliver new drug products to the market. Biological Drug Products begins with generalconsiderations for the development of any biological drug productand then explores the strategies and challenges involved in thedevelopment of specific types of biologics. Divided into fiveparts, the book examines: Part 1: General Aspects Part 2: Proteins and Peptides Part 3: Vaccines Part 4: Novel Biologics Part 5: Product Administration/Delivery Each chapter has been prepared by one or more leading experts inbiological drug development. Contributions are based on acomprehensive review and analysis of the current literature as wellas the authors' first-hand experience developing and testing newdrugs. References at the end of each chapter serve as a gateway tooriginal research papers and reviews in the field. By incorporating lessons learned and future directions forresearch, Biological Drug Products enables pharmaceuticalscientists and students to improve their success rate in developingnew biologics to treat a broad range of human diseases.

Liver Intra arterial PRRT with 111In OctreotideLiver Intra arterial PRRT with 111In Octreotide

Monoclonal antibody and peptide- targeted radiotherapy of cancer, Chapter 9. New Jersey: Wiley; 2010. References 1. Bosman FT, Carneiro F, Hruban RH, et al. 23 Progression-Free Survival and Response Rate in Neuroendocrine ...

Author: Georgios S. Limouris

Publisher: Springer Nature

ISBN: 9783030707736


Page: 270

View: 111

This book describes in detail a clinical project that reveals the tumoricidal efficacy of Auger and internal conversion electrons, emitted from n.c.a. 111In and implemented in oncology as a treating armamentarium for peptide receptor radionuclide therapy (PRRT), targeting small size (ø ≤ 20 mm) tumors and micro-metastases. The keen interest in n.c.a. 111In began when it was observed that its Auger electron emission could be highly radiotoxic, due to its high LET when it decayed in the vicinity of cellular DNA. The somatostatin analog octreotide, labeled with [111In-diethylenetriaminepentaacetic acid (DTPA0-D-Phe1)] is an established diagnostic agent for the imaging of somatostatin receptor-positive neuro- (or non-neuro) endocrine tumors. It relies on receptor-mediated binding, internalization and installation in the lysosomes in the proximity of the nucleus; administered in large doses, loco-regionally, via the feeding artery of solid tumors, can be highly radiotoxic if they over-express somatostatin receptors, mainly of the sst2 histotype. The book compares the results between i.v. and i.a. implementation in more than 80 patients after over 800 i.a. infusions in neuroendocrine tumors, meningiomas, paragangliomas and colorectal carcinomas in a single Institute (Aretaieion University Hospital) and encourages the i.a. way, leading to “tumor melting”, while minimizing the toxicity to healthy peritumoral liver tissue and critical organs (kidneys and bone marrow). The volume is an invaluable tool for nuclear medicine physicians, interventional radiologists and oncologists dealing with radiopeptide therapies.

Human Radiation InjuryHuman Radiation Injury

RIT and other forms of systemically targeted radiation therapy use antibodies, antibody fragments, constructs, fusion peptides or peptides to target radiation-emitting radionuclides to tumors.27 In most cases, the radionuclide is ...

Author: Dennis C. Shrieve

Publisher: Lippincott Williams & Wilkins

ISBN: 9781451153217


Page: 560

View: 342

Human Radiation Injury is a concise but thorough presentation of known toxicities of radiation exposure in humans. This unique text is the only single reference available that studies the risks to humans from medical, environmental, and accidental or terrorist-related exposure to radiation. The chapters cover modern understanding of the molecular and cellular events involved in radiation injury, the known dose-effect relationships for human organ systems, and a full discussion of normal tissue toxicity related to therapeutic radiation. Recommended guidelines are outlined and the best available treatments following injury are also detailed. A companion website offers the fully searchable text and an image bank.

Radionuclide Peptide Cancer TherapyRadionuclide Peptide Cancer Therapy

Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation ... Bispecific monoclonal antibodymediated targeting of an indium-111- labeled DTPA dimer to primary colorectal ...

Author: Marco Chinol

Publisher: CRC Press

ISBN: 9781000611571


Page: 376

View: 545

Offering lower toxicity and higher accuracy than conventional therapies, this source offers illustrative coverage of this new method to treat tumors associated with brain, breast, lung, and neuroendocrine cancers. Accompanied by a CD offering color images, radiolabeling procedures, and tips on radiopharmceutical administration, this source will off

Advances in Nuclear Oncology Advances in Nuclear Oncology

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. ... Polymer–peptide conjugates for angiogenesis targeted tumor radiotherapy.

Author: Emilio Bombardieri

Publisher: CRC Press

ISBN: 9780203089675


Page: 530

View: 778

The diagnostic and therapeutic achievements in radiopharmaceuticals and nuclear medicine instrumentation – PET, SPECT, MR, CT and their hypbrids PET-CT and SPECT-CT – are the result of the interdisciplinary research efforts of cell-biologists, chemists, pharmacologists, physicists, computer-scientists, engineers, nuclear medicine physicians, and oncologists. The clinical implications of these achievements have made nuclear medicine indispensable in the management of cancer. This superbly illustrated text on modern nuclear medicine applications in the diagnosis and treatment of cancer describes the state of the art and the current position of nuclear medicine in the light of these recent developments. It is intended as a valuable update also for non-nuclear medicine specialists working in oncology. Nuclear medicine as part of molecular imaging and therapy has changed radically in the last decade. The growing importance and clinical impact of these changes in the near future has impelled the internationally renowned editors and contributors to put them on record in Advances in Nuclear Oncology.

Gunderson Tepper s Clinical Radiation Oncology E BookGunderson Tepper s Clinical Radiation Oncology E Book

Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with ... High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

Author: Joel E. Tepper

Publisher: Elsevier Health Sciences

ISBN: 9780323672474


Page: 1648

View: 441

A comprehensive, multidisciplinary resource for the entire radiation oncology team, Gunderson & Tepper’s Clinical Radiation Oncology, 5th Edition, thoroughly covers all aspects of this complex and dynamic field. Concise, templated chapters cover the basic biology of oncologic disease processes as well as updated treatment algorithms, the latest clinical guidelines, and state-of-the-art techniques and modalities. More than 1,000 images—detailed anatomy drawings, radiographic images, and more—provide outstanding visual support for every area of the text. Divides content into three distinct sections for quick access to information: Scientific Foundations, Techniques and Modalities, and Disease Sites. Disease Site chapters include overviews summarizing the most important issues and concluding discussions on controversies and problems. Features new and expanded content on molecular and cellular biology and its relevance in individualized treatment approaches, stereotactic radiation therapy, radiosurgery, proton therapy, biologic therapy, precision radiation therapy, targeted radiation, dosing guidelines for better quality of life and improved patient outcomes, and more. Includes new chapters on Radiation Physics: Particle Therapy, Interventional Radiology, Radiation Therapy in the Elderly, Palliative Care, Quality and Safety, and Immunotherapy with Radiotherapy. Provides guidance on single-modality and combined-modality approaches, as well as outcome data including disease control, survival, and treatment tolerance. Includes access to videos on Intraoperative Irradiation, Prostate Brachytherapy, Penile Brachytherapy, and Ocular Melanoma.

Targeted Radionuclide TherapyTargeted Radionuclide Therapy

Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II ... of indium-111 and yttrium-88 labeled dendrimer-1B4M- DTPA and its conjugation with anti-Tac monoclonal antibody.

Author: Tod W. Speer

Publisher: Lippincott Williams & Wilkins

ISBN: 9781451153262


Page: 608

View: 973

Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank.